Abstract:Xinwei Zhou, 1, &ast Ke Lin, 2, &ast Liangmin Fu, 1, &ast Fei Liu, 3, &ast Hansen Lin, 1 Yuhang Chen, 1 Bowen Zhuang, 2 Hui Liang, 4 Qiong Deng, 4 Zhu Wang, 4 Wei Chen, 1 Junhang Luo, 1, 5 Jiazheng Cao, 6 Pengju Li 1 1 Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; 2 Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; 3 Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; 4 Department of Urology, Affiliated Longhua People's Hospital, Southern Medical University, Shenzhen, People's Republic of China; 5 Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China; 6 Department of Urology, Jiangmen Central Hospital, Jiangmen, People's Republic of China &astThese authors contributed equally to this work Correspondence: Pengju Li, Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, No. 58, Zhongshan Road II, Guangzhou, 510080, People's Republic of China, Tel +86-20-87618227, Email Jiazheng Cao, Department of Urology, Jiangmen Central Hospital, Haibang Street 23, Jiangmen, 529030, People's Republic of China, Tel +86-750-3165500, Email Background: Triggering receptors expressed by myeloid cells-1 (TREM1) is a receptor belonging to the immunoglobulin superfamily and plays an important role in pro-inflammation in acute and chronic inflammatory disorders. However, the understanding of the immunomodulatory roles of TREM1 in the tumor microenvironment remains incomplete. Methods: The expression patterns of TREM1 mRNA in tumors and adjacent normal tissues were compared by analyzing data obtained from the Genotype-Tissue Expression and The Cancer Genome Atlas datasets. Survival analysis was performed to determine the prognostic value of TREM1. Functional enrichment analysis was applied to decipher the discrepancy in biological processes between high- and low-TREM1 groups across various cancers. The correlation between TREM1 and immune cell infiltration determined by using multiple algorithms was evaluated with the Pearson method. Four independent immunotherapy cohorts were adopted to validate the role of TREM1 as a biomarker. Results: TREM1 was elevated in most cancers as verified with clinical samples. Overexpression of TREM1 was linked with undesirable prognosis in patients. Further analysis revealed that TREM1 was positively correlated with immune response, pro-tumor pathways, and myeloid cell infiltration, while being negatively correlated with CD8 + T cell (including infiltration level and biological processes). Concordantly, tumors with high TREM1 levels were more resistant to immunotherapy. Through connective map analysis, therapeutically potential compounds like tozasertib and TPCA-1 were identified, which can be used synergistically with immunotherapy to improve the poor prognosis of patients with high TREM1 levels. Conclusion: Through a systematic and comprehensive pan-cancer analysis, we demonstrated that overexpression of TREM1 in tumors correlated closely with unfavorable outcome, infiltration of immune-suppressive cells, and immune regulation, which highlights its potential use as a tumor prognostic biomarker and a novel target for immunotherapy. Keywords: triggering receptors expressed by myeloid cells-1, pan-cancer, prognostic biomarker, tumor microenvironment, clear cell renal cell carcinoma, immunotherapy The tumor microenvironment (TME) is a collective term that includes tumor cells and the non-neoplastic components with which they interact. Changes in the TME often affect multiple biological functions in tumors. 1 Although "inflammatory" type tumors characterized by high immune cell infiltration are considered to have a better prognosis and a better response to immunotherapy, chronic inflammation is inextricably linked with tumor development and immune escape. 2 Studies have confirmed that the presence of long-term chronic infection is highly related to the risk of tumors at the same location, and many cancers occur at the sites of chronic inflammation. 3 Cancer-related inflammation is even considered the seventh hallmark of cancer. 4 Ther -Abstract Truncated-

The Interaction of HMGB1 with the Proinflammatory TREM-1 Receptor Generates Cytotoxic Lymphocytes Active against HLA-Negative Tumor Cells

Triggering Receptor Expressed on Myeloid Cells-2 (TREM-2) Elicited by Lung Cancer Cells to Facilitate Tumor Immune Evasion.

Targeting Inflammation Driven by HMGB1

Activation of triggering receptor expressed on myeloid cells-1 protects monocyte from apoptosis through regulation of myeloid cell leukemia-1.

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

TREM1 activation of myeloid cells promotes antitumor immunity

High Mobility Group Box 1 Protein (HMGB1) As an Immune-Modulating Factor for Polarization of Human T Lymphocytes

HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2

HMGB1 as a DNA-binding cytokine

TREM-1, an Inflammatory Modulator, is Expressed in Hepatocellular Carcinoma Cells and Significantly Promotes Tumor Progression

TREM1: Activation, signaling, cancer and therapy

HMGB1 Is a Therapeutic Target for Sterile Inflammation and Infection

Relationship of high mobility group boxl and inflammation

Activation of Toll-Like Receptor 5 Immune Signaling by Hmgb1

Overexpression of TREM1 is Associated with the Immune-Suppressive Microenvironment and Unfavorable Prognosis in Pan-Cancer

Advance of TREM-1 and Its Role in Sepsis

HMGB1 as a therapeutic target in disease

The Expression of HMGB1 on Microparticles Released during Cell Activation and Cell Death In Vitro and In Vivo

Signaling of High Mobility Group Box 1 (HMGB1) through Toll-like Receptor 4 in Macrophages Requires CD14

HMGB1 and RAGE in Inflammation and Cancer

HMGB1: A signal of necrosis